

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE IB/II CLINICAL TRIAL OF SYS6090 INJECTION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Phase Ib/II clinical trial (Study Protocol No.: SYS6090-007) of SYS6090 Injection (the “**Product**”) developed by the Group, for the treatment of hepatocellular carcinoma has been officially initiated at the first centre in China.

The Product, with a registration classification as a Class 1 therapeutic biological product, is a recombinant fully human anti-programmed cell death receptor 1 (“**PD-1**”) and interleukin-15 (“**IL-15**”) fusion protein. It targets PD-1-positive tumour-infiltrating immune cells through its left arm, to block the immunosuppressive function caused by the interaction between PD-1 and programmed death ligand 1 (PD-L1); meanwhile, it binds to the IL-15 receptor through its right arm to activate its downstream signalling pathways, further promoting the activation and proliferation of relevant immune cells. Pre-clinical study results showed that the Product significantly inhibited tumour growth with favourable safety and tolerability, and demonstrated superior pharmacodynamic activity compared to other PD-1 monoclonal antibody drugs and IL-15 drugs.

Previously, the Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People’s Republic of China for the Product in July 2026, and initiated the SYS6090-007 clinical trial following the approval. The approved clinical trial is an open-label, multi-centre Phase Ib/II clinical study aimed at evaluating the safety, tolerability, and efficacy of the combination therapy of the Product in participants with hepatocellular carcinoma.

Based on the results of this study, the Group will subsequently continue to advance the Phase III clinical trial of the combination therapy of the Product in participants with hepatocellular carcinoma, to further verify the efficacy and safety of the Product. Currently, the recruitment and screening of subjects for the SYS6090-007 study are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 19 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.